| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/11/2002 | WO2001010907A9 Therapeutic polypeptides and methods for using same |
| 07/11/2002 | WO2001010454B1 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 07/11/2002 | WO2001010205A9 Methods and materials relating to cd39-like polypeptides |
| 07/11/2002 | WO2001000798A9 Cloning and expressing of human cathepsin k in mammalian cells |
| 07/11/2002 | WO2000075173A3 Peptide fragments of colostrinin |
| 07/11/2002 | WO2000073321A9 Human tumor necrosis factor receptor tr10 |
| 07/11/2002 | WO2000067024A9 Cancer treatment with endothelin receptor antagonists |
| 07/11/2002 | WO2000067016A9 Methods for the identification of compounds for the treatment of alzheimer's disease |
| 07/11/2002 | WO2000066179A9 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 07/11/2002 | WO2000064488A9 Somatic transgene immunization and related methods |
| 07/11/2002 | WO2000062067A9 Novel transduction molecules and methods for using same |
| 07/11/2002 | WO2000061747A9 Clasp-2 transmembrane proteins |
| 07/11/2002 | WO2000049937A9 Trpm-2 antisense therapy |
| 07/11/2002 | US20020091375 Stent lining |
| 07/11/2002 | US20020091249 Human tumor suppressor polypeptides |
| 07/11/2002 | US20020091248 Nucleotide sequences coding polypeptide for use in the treatment of Bardet-Biedl Syndrome, hearing loss, retinis pigmentosa, obesity, hypogonadism, diabetes and cardiovascular disorders |
| 07/11/2002 | US20020091247 Polycyclic aromatic hydrocarbon induced molecules |
| 07/11/2002 | US20020091246 Dendritic cell co-stimulatory molecules |
| 07/11/2002 | US20020091244 Nucleotide sequences for use in diagnosis and treatment of cancer and immunological disorders |
| 07/11/2002 | US20020091243 Factors affecting tumor necrosis factor receptor releasing enzyme activity |
| 07/11/2002 | US20020091239 Human chemokine |
| 07/11/2002 | US20020091238 Nuclelotide sequences coding transport protein for use in treatment of cancer, pain, aberrant cellular proliferation and/or differentiation, hormonal and liver disorders |
| 07/11/2002 | US20020091236 Nucleotide sequences coding preferential polypeptide for use in detection of bactericides |
| 07/11/2002 | US20020091235 St - B17 serotonin receptor |
| 07/11/2002 | US20020091234 Adjuvant for enhancing immune response to preferential immunogen |
| 07/11/2002 | US20020091230 Made from a bis/gamma-hydroxyhydrocarbyl/ ester of terephthalic acid and a phosphorodichloridate; biocompatible before and upon biodegradation |
| 07/11/2002 | US20020091229 Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| 07/11/2002 | US20020091160 Administering orally a source of at least one of L-arginine and L-lysine as other than a natural food source |
| 07/11/2002 | US20020091128 Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| 07/11/2002 | US20020091125 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| 07/11/2002 | US20020091115 Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| 07/11/2002 | US20020091104 Protein tyrosine phosphatases inhibitors, especially as antidiabetic agents |
| 07/11/2002 | US20020091098 Also administering to the subject an effective amount of an mda-7 protein. |
| 07/11/2002 | US20020091096 Nucleic acid, including DNA, immunization against disease caused by infection by a strain of Chlamydia employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia |
| 07/11/2002 | US20020091095 Modulation of Fas and FasL expression |
| 07/11/2002 | US20020091094 Glutamic acid decarboxylase (GAD) based delivery system |
| 07/11/2002 | US20020091090 Somatostatin antagonists and agonists |
| 07/11/2002 | US20020091088 Administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone |
| 07/11/2002 | US20020091086 Peptides that block viral infectivity and methods of use thereof |
| 07/11/2002 | US20020091085 Src SH3 binding peptides and methods of isolating and using same |
| 07/11/2002 | US20020091084 Human calcineurin B-like protein (CAB) and polynucleotides which identify and encode CAB. |
| 07/11/2002 | US20020091083 Substance which regulates the type-I collagen gene transcription regulating ability |
| 07/11/2002 | US20020091082 Inhibiting VEGF-KDR signaling pathway components, e.g., PKC-zeta and/or PI3 kinase 1. |
| 07/11/2002 | US20020091081 Administering therapeutically active dosages of peptides containing specific amino acid sequences or antibodies that bind to cell membrane antigens on the surface of rapidly dividing endothelial cells. |
| 07/11/2002 | US20020091080 OBG3 globular head and uses thereof for decreasing body mass |
| 07/11/2002 | US20020091079 An empty sc-MHC class II molecule comprising a peptide binding groove and a class II beta 2 chain comprising at least one amino acid substitution or deletion; immunosuppressants |
| 07/11/2002 | US20020091078 Treating diabetes, especially Type II diabetes |
| 07/11/2002 | US20020091077 Osteogenic protein is provided alone or dispersed in a biocompatible non-rigid, amorphous carrier having no defined surfaces |
| 07/11/2002 | US20020091076 Staphylokinase derivatives |
| 07/11/2002 | US20020090724 Activation of regulatory T cells by alpha-melanocyte stimulating hormone |
| 07/11/2002 | US20020090721 Mucin-containing delivery vehicle for the transport of biomolecules |
| 07/11/2002 | US20020090719 Expression vectors containing hybrid ubiquitin promoters |
| 07/11/2002 | US20020090715 Method for the preparation of a viral vector by inter-molecular homologous recombination |
| 07/11/2002 | US20020090712 Rab proteins |
| 07/11/2002 | US20020090711 Generating blood glycoprotein; obtain solution containing glycoprotein, incubate in preferential buffer, recover processed glycoprotein |
| 07/11/2002 | US20020090703 Mammalian protein phosphatases |
| 07/11/2002 | US20020090696 Treating neurological disorders using human apoptosis inhibiting protein |
| 07/11/2002 | US20020090695 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 07/11/2002 | US20020090694 Human Hox C10 and polynucleotides encoding |
| 07/11/2002 | US20020090693 Novel human sodium-dependent phosphate cotransporter |
| 07/11/2002 | US20020090692 Novel polynucleotides and polypeptides encoded thereby |
| 07/11/2002 | US20020090683 Tumor necrosis factor-gamma |
| 07/11/2002 | US20020090682 Novel haemopoietin receptor and genetic sequences encoding same |
| 07/11/2002 | US20020090681 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 07/11/2002 | US20020090679 Lung growth factor variant |
| 07/11/2002 | US20020090676 TNF receptors, TNF binding proteins and DNAs coding for them |
| 07/11/2002 | US20020090674 Nucleic acids, proteins, and antibodies |
| 07/11/2002 | US20020090673 Nucleic acids, proteins, and antibodies |
| 07/11/2002 | US20020090672 Nucleic acids, proteins, and antibodies |
| 07/11/2002 | US20020090671 Bone stimulating factor |
| 07/11/2002 | US20020090670 Cysteine/glycine rich peptides |
| 07/11/2002 | US20020090658 Diagnosing connective tissue defects; obtain sample, screen sample for the presence of degradation protein, amplified concentrations of protein indicate connective tissue defects |
| 07/11/2002 | US20020090657 Detecting preferential binding particle in sample; obtain cell, incubate with modulator, monitor forming of complex, compare to control, reduction in complex formation indicates bound receptor |
| 07/11/2002 | US20020090654 Polypeptide for use in the treatment of collagenase defects |
| 07/11/2002 | US20020090653 Methods of treating pervasive development disorders |
| 07/11/2002 | US20020090651 Isolated FGF receptor |
| 07/11/2002 | US20020090647 Peptide for use in treatment of nervous system disorders |
| 07/11/2002 | US20020090646 Calcitonin-related molecules |
| 07/11/2002 | US20020090610 Polypeptide for use in the detection, diagnosis, prevention and treatment of vial disease |
| 07/11/2002 | US20020090609 Diagnostics and therapy of diseases associated with HHV-8 infections |
| 07/11/2002 | US20020090441 Phytopharmaceutical food products or integrators |
| 07/11/2002 | US20020090416 Method of enhancing absorption and utilization of protein |
| 07/11/2002 | US20020090377 Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| 07/11/2002 | US20020090374 Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| 07/11/2002 | US20020090373 ADAMTS polypeptides, nucleic acids encoding them, and uses thereof |
| 07/11/2002 | US20020090372 Isolated polypeptides used in vaccines and pharmaceuticals for treatment of prostate cancer |
| 07/11/2002 | US20020090371 Orally or enterally administering to the mammal an effective immunosuppressive dose of a plant material derived from a plant transformant capable of producing antigen or an immunosuppressive fragment or its derivative |
| 07/11/2002 | US20020090368 Therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
| 07/11/2002 | US20020090367 Therapeutic treatment of upper respiratory infections |
| 07/11/2002 | US20020090366 Administering lymphotoxin beta receptor-alpha/beta heteromeric complex and a pharmaceutically acceptable carrier for therapy or reducing the advancement, severity or effects of neoplasia |
| 07/11/2002 | US20020090364 Cells designed as traps and their use as medicines |
| 07/11/2002 | US20020090355 Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene |
| 07/11/2002 | US20020090353 Locally administering to the tumor an antigen-releasing agent, locally administering to tumor leukocyte attractant and tumor interferon-gamma (IFN-g) and a second type 1 inflammatory response-(IR1-)promoting agent for therapy of tumor |
| 07/11/2002 | US20020090352 Compositions and methods for use in modulating immune system function |
| 07/11/2002 | DE10131404A1 Stabilized liquid formulation, useful as a pharmaceutical composition or diagnostic reagent, comprises blood coagulation Factor VII activating protease and an aminoacid or derivative, e.g. ornithine or creatine, as stabilizer |
| 07/11/2002 | DE10100052A1 Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors |
| 07/11/2002 | DE10064195A1 Verwendung einer Zusammensetzung zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens Use of a composition for the stimulation of nerve growth, to inhibition of scar tissue formation and / or reduction of secondary damage |
| 07/11/2002 | DE10061110A1 Expression der Keratingene 8 und 18 zur Therapie von Tumoren, insbesondere des Mammakarzinoms Expression of keratin genes 8 and 18 for the treatment of tumors, especially of breast cancer |
| 07/11/2002 | CA2789161A1 Pharmaceutical composition to prevent tissue damage due to arterial blood flow failure |
| 07/11/2002 | CA2680475A1 Sustained-release preparation |